CD19 and congenital rubella syndrome: The 15 patients in which CRS was severe were effectively treated with the anti-IL-6-receptor antibody, tocilizumab.152 Important causes of treatment failure included the loss of circulating CAR-Ts and the expansion of a CD19-negative clone.